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ABSTRACT  
Solid lipid nanoparticles (SLNs) of zolmitriptan were 
produced by solvent emulsification-diffusion technique. Soya 
lecithin and poloxamer 188 were used as surfactants and 
stabilizers of the particles. The formulations were optimized for 
independent variables (amount of stearic acid, amount of lecithin 
and homogenization time) in order to achieve desired particle size 
with maximum percent entrapment efficiency (% EE). Prepared 
SLNs were characterized by transmission electron microscopy 
(TEM), atomic force microscopy (AFM) and zeta potential 
measurements. To achieve our goal, eight formulations (F1–F8) of 
SLNs were prepared by solvent injection technique and optimized 
by 23 full-factorial design. The responses of the design were 
analyzed using Minitab 15. On the basis of software analysis, 
formulation F8 was selected as optimized formulation and was 
evaluated for the independent parameters. Optimized formulation 
showed particle size of 340nm, percent entrapment efficiency (EE) 
of 81.36 and 79.11% of in-vitro drug release after 24h. The 
release kinetics of the optimized formulation best fitted the 
Higuchi model. 
 
Key words: solid lipid nanoparticles, zolmitriptan, solvent emulsification-
diffusion technique, in-vitro release.  
 
INTRODUCTION  
Migraine is a common and frequently 
disabling headache disorder characterized by 
recurrent episodic attacks of moderate to 
severe headache variably accompanied by 
neurological, gastrointestinal and/or autonomic 
symptoms (Goadsby et al., 2002). There are two 
major forms of migraine: migraine without aura 
and migraine with aura. The aura consists of 
focal neurologic symptoms (usually visual 
symptoms) that precede or accompany 
headache, and it appears in 15-25% of migraine 
sufferers. Migraine affects approximately 18% 
of women and 6% of men in western countries, 
and 20-40% of patients experience an attack 
frequency of greater than one per month 
(Belvis et al., 2009).  
Zolmitriptan, 4S-4-({3-[2-(dimethylamino) 
ethyl]-1H-indol-5-yl} methyl)-1, 3-oxazolidin -
2-one, is a second generation triptan prescribed 
for patients with migraine attacks, with or 
without an aura, and cluster headaches. It has a 
selective action on serotonin (5-HT1B/1D) 
receptors and is very effective in reducing 
migraine symptoms, including pain, nausea, and 
photo-or phonophobia (Gayathri, et al., 2000). 
Patients with migraine generally suffer from 
nausea and vomiting; oral treatment can 
therefore be inconvenient or could fail (Kolsure, 
et al., 2012). The inherent shortcomings of 
conventional drug delivery and the potential of 
nanoparticles as drug delivery systems have 
offered tremendous scope for researchers in 
this field and are fast moving from concept to 
reality. 
Nanoparticles based on solid lipids have 
been proposed as a promising alternative to 
colloidal drug delivery system, polymeric 
nanoparticles, and liposomes. Compared to 
traditional carriers, the solid lipid nanoparticles 
(SLNs) combine the advantages of polymeric 
nanoparticles and o/w fat emulsions for          
drug administration such as good tolerability, 
lower cytotoxicity (Muller, et al., 1996), higher 
bioavailability by oral administration (Yang, et 
al., 1999), and increase in the drug stability 
(Mehnert and Mader, 2001). Other advantages 
of lipid excipients, such as biodegradability and 
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cost effectiveness (Mukherjee, et al., 2007), 
promote their use as novel drug carriers. 
Consisting of physiological and biodegradable 
lipids, lipid nanoparticles are suitable for the 
incorporation of lipophilic, hydrophilic, and 
poorly water-soluble drugs within the lipid 
matrix in considerable amounts (Bunjes, et al., 
2001). Lipidic carriers used to prepare SLNs 
can be highly purified lipids such as tristearin or 
tripalmitin, hard fats such as stearic acid or 
behenic acid, waxes such as cetylpalmitate, and 
acylglycerol mixtures such as compritol or 
glycerylmonostearate (GMS) (Souto, 2006). 
In the present study, stearic acid has 
been used to formulate SLNs. The selection of 
stearic acid was its lipid matrix is made from 
physiological lipids that decrease the danger of 
acute and chronic toxicity in epidemiologic and 
clinical studies. Stearic acid was associated with 
lowered LDL cholesterol in comparison with 
other saturated fatty acids indicating it less 
unhealthy than other saturated fatty acids. 
 
MATERIAL AND METHODS 
Zolmitriptan was a gift from Zydus 
Cadila Health Care Limited, Ahmedabad. 
Stearic acid (Molar mass 284.48g mol−1, melting 
point 69.6°C, density 0.84g/cm3 at 70°C) was 
purchased from Clearsynth Labs, Andheri, 
Mumbai, India. Soya lecithin (Epikuron, 200) 
was purchased from LeciImpex, Indore, M.P. 
PoloxamerF 68 (molecular weight 12 kDa) was 
purchased from Balaji Drugs, Surat. Dialysis 
bag (molecular weight cut off (MWCO) 12-
14kDa; pore size 2.4nm) was supplied by Hi 
Media, Mumbai, India. Other chemicals used 
were of analytical grade. 
 
Experimental design of SLNs 
In this study, a 23 full-factorial expe-
rimenttal design was used to optimize SLNs. In 
this ‘2’ indicates levels i.e. higher and lower and 
‘n’ is factor i.e. concentration of stearic acid, 
concentration of soya lecithin and time for 
homogenization. Eight formulations of SLNs 
(F1 to F8) were designed. In order to optimize, 
the amount of stearic acid (X1), amount of 
lecithin (X2) and homogenization time (X3) 
were selected as independent variables. Each 
factor was set at a high level and low level. The 
actual values and coded values of different 
variables are given in table I. The particle size 
and % entrapment efficiency (EE) were taken 
as response parameters. 
 
Preparation of SLNs 
Solvent emulsification-diffusion technique 
Solid lipid nanoparticles of zolmitriptan 
were prepared by the solvent emulsification-
diffusion technique. The solvent (ethyl acetate) 
and water were mutually saturated for 10min at 
room temperature in order to generate 
equilibrium between the two liquids. Heating 
up to 70°C was required to solubilize the lipid, 
the saturation step was performed at this 
temperature. Typically, specified amount of 
lipid, 10mg of drug zolmitriptan were dissolved 
in 10mL of water-saturated solvent and               
this organic phase (internal phase) was 
emulsified with 20mL of the solvent-          
saturated aqueous solution containing 10% w/v 
of stabilizer(dispersion medium) using a 
mechanical stirrer at 3000rpm for 15min. After 
formation of an oil in-water emulsion, 80mL of 
water (dilution medium) was added to the 
system in order to allow solvent diffusion into 
the continuous phase thus causing the 
aggregation of the lipid in nanoparticles. When 
heating was required to dissolve the lipid, both 
phases were maintained at 70°C and the 
diffusion step was performed either at RT or at 
the temperature under which the lipid was 
dissolved. Throughout the process constant 
stirring was maintained. Thereafter, the 
dispersion was centrifuged to 10,000rpm for 
30min at 10°C in Remi cooling centrifuge 
(Model C-24BL, VCAO-779, Vasai, India), and 
aggregates were purified by dialysis bag and 
resuspended to 10mL distilled water containing 
4% poloxamer F68 (by weight) as stabilizer 
with stirring at 1,000rpm for 10min. 
 
Purification of zolmitriptan-loaded SLNs 
Purification of zolmitriptan-loaded SLNs 
was done by using dialysis technique. 
Sedimented soft pellet was taken in the         
dialysis bag and sealed at both ends. The 
dialysis bag was then immersed into 100mL of 
distilled water containing 0.2% w/v sodium 
lauryl sulphate and stirred at 100 rpm for 
30min. Five milliliter of sample was withdrawn 
at different time intervals of 5, 10, 15, and 
30min. The samples were diluted appropriately              
and analyzed for amount of drug by UV/ 
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visible spectrophotometer (JASCO V-30 UV 
Spectrophotometer) at 283nm (Shah and 
Pathak, 2010). 
 
Characterization of zolmitriptan SLNs  
Transmission electron microscopy  
Structure  of  the  SLNs were  studied  
using Morgagni  268D transmission electron 
microscopy  (TEM)  FEI, Netherland operating  
at 70KV  and  capable of point to point 
resolution. Combination of bright field imaging 
at increasing  magnification  and  diffraction  
modes  were  used  to  reveal  the  form  and  
size  of  SLNs.  In  order  to  perform  the  
TEM  observations,  a  drop  of SLN 
dispersion  was  applied  on  carbon  coated  
grid  with  2%  phosphotungstic  acid (PTA) 
and was left for 30sec. The dried coated grid 
was taken on a slide and covered with a cover 
slip. The slide was observed under the electron 
microscope (Garcia-Fuentes et al., 2003). 
 
Atomic force microscopy (AFM) 
By using AFM one can not only image 
the surface in atomic resolution but also 
measure the force at nano-newton scale. The 
sample preparation for AFM is simple and 
quick and it allows the material to be preserved 
in its original form. For AFM study, one           
drop of formulation was spread out 
homogenously on separate mica piece (5mm × 
5mm) and the sample was then allowed to dry 
at room temperature for one day before 
imaging at a scan speed of 2Hz (Dubes et al., 
2003). 
 
Entrapment efficiency 
 Entrapment efficiency (EE) of SLNs 
was determined by centrifugation method          
with rotor at 10,000rpm for 30min. The 
supernatant was collected. The quantity of drug 
present in the supernatant was determined by 
the UV Spectrophotometer. The entrapment 
efficiency was calculated using the following 
equation. 
EE(%)=(Winitial-Wfree)/Winitial X 100 
where, Winitial is the total amount of 
zolmitriptan used in preparation of solid lipid 
nanoparticles and Wfree is the amount of 
zolmitriptan detected in the supernatant, 
respectively (Bhaskar et al., 2009, Sarmento et 
al., 2007).  
Drug loading capacity 
The drug loading (DL) capacity of 
Zolmitriptan was also calculated using the 
formula:  
DL (%)=(Winitial – Wfree)/ Wlipid X 100 
where, Winitial is the total amount of 
zolmitriptan used in preparation of solid lipid 
nanoparticles, Wfree is the amount of 
zolmitriptan detected in the supernatant, and 
Wlipid is the amount of lipid in the preparation 
of solid lipid nanoparticles, respectively (Lv et 
al., 2009).  
 
Particle size distribution, zeta potential and 
polydispersity index (PDI) 
The zeta potential and size distribution 
of SLNs were measured in triplicates in 
multimodal move (Doijad et al., 2008). The 
particle size distribution and polydispersity 
index were determined using computerized 
Malvern instrument particle size analyser v2.0 
(Malvern UK) and zeta potential was 
determined by using Malvern zetasizer 
inspection system v2.2 (Malvern UK) at 25°C. 
Prior to the measurement, SLNs were diluted 
with distilled water and the measurements were 
taken in triplicate (n=3). 
 
In-vitro release 
In vitro release was evaluated by using a 
dialysis membrane diffusion technique (Reddy 
et al., 2005). The drug release from Zolmitriptan 
SLNs (ZOL-SLNs) was performed in PBS (pH 
7.4) using dialysis membrane. A dialysis 
membrane (Himedia, Mumbai) weight cut off 
between 12.000 and 14.000 was used. The 
membrane was soaked in distilled water for 12 
hours before the release study. Two mL ZOL-
SLNs suspension was placed in dialysis 
membrane tied at both ends to form dialysis 
bags and these dialysis bags were subsequently 
placed in flasks containing 50mL dissolution 
medium at 100rpm at 37°C. Aliquots of the 
dissolution medium were withdrawn at each 
time interval and the same volume of fresh 
dissolution medium was added to the flask to 
maintain a constant volume. Drug 
concentration in the dissolution medium was 
determined.The absorbance was used to 
calculate concentration using calibration curve. 
The experiments were performed in triplicate. 
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Statistical analysis 
Statistical analysis was performed with 
Minitab 15 software. Results were expressed as 
mean ± standard deviation (SD). Statistical 
significance was determined using analysis of 
variance (ANOVA) with P≤0.05 as a minimal 
level of significance.  
 
RESULTS AND DISCUSSION 
Formulation considerations 
SLNs were prepared by solvent 
emulsification-diffusion technique that relies on 
the rapid diffusion of the solvent across the 
solvent-lipid interface with the aqueous phase. 
Thus, the diffusion rate of the organic solvent 
through the interface seems to be a critical 
parameter for particle size determination 
(Schubert et al., 2003). The major problem with 
the formulation of SLNs is its separation. 
Owing to their small size and low density of 
lipids, SLNs present difficulty in settling upon 
centrifugation. To overcome this problem, in 
the present study, the pH of the dispersion was 
reduced to 2-3 to adjust the zeta potential for 
aggregation of SLNs (Hu et al., 2002) and 
facilitate centrifugation and consequently 
separation. 
A possibility of presence of zolmitriptan 
particles in the sediment of zolmitriptan-loaded 
SLNs was explored.  It is suggested that these 
particles can potentially interfere in the in 
vitro and in vivo behavior of zolmitriptan-loaded 
SLNs. Therefore, free drug particles were 
removed from the sediment of SLNs by 
purification by dialysis technique. Dialysis 
technique was considered suitable, as 
zolmitriptan with a low molecular weight could 
be efficiently removed using dialysis bag made 
of Himedia membrane. Consequently, 
purification was accomplished by monitoring 
percent free drug removed after 5, 10, 15, and 
30min, respectively. Initially, the percent free 
drug removed increased with time and reached 
plateau levels by 30min. Slowest% drug release 
using dialysis technique after 30 min was 
observed by formulation F8 (2.40%) and 
highest % drug release was observed by 
formulation F4 (20.66%).  
ANOVA was used to check any 
significant difference between the percent free 
drug removed at 15 and at 30 min. It was 
observed that although the extent of free drug 
in various SLN formulations was significantly 
different (p < 0.05), there was no significant 
difference in percent free drug removed after 
purification time of 15 and 30min (p > 0.05). 
Thus, free zolmitriptan from sediment of SLNs 
could be efficiently removed after purification 
for 15min and hence was used throughout the 
experiment. 
 
Statistical analysis of experimental data 
by minitab 15 software 
The results of the experimental design 
were analyzed using Minitab software that 
provided  considerable  useful  information and 
Table I.  Formulations of zolmitriptan SLNs 
 
Code Experiment Factor 
A 
Factor 
B 
Factor 
C 
Particle size 
(nm) 
Entrapment 
efficiency (%) 
F1 1 - - - 410 57.12 
F2 A + - - 450 76.42 
F3 B - + - 320 58.36 
F4 Ab + + - 390 75.48 
F5 C - - + 360 60.14 
F6 Ac + - + 430 77.81 
F7 Bc - + + 250 59.16 
F8 Abc + + + 340 81.36 
Coded values 
Factor A = Amount of stearic acid (low level 200mg, high level 600mg) 
Factor B = Amount of soya lecithin (low level 200mg, high level 800mg) 
Factor C = Stirring time (low level 15min, high level 30min) 
- denotes lower and + denotes higher limit, respectively.  
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reaffirmed the utility of statistical design for 
conduct of experiments. The selected 
independent variables like the amount of stearic 
acid, amount of lecithin, and stirring time 
significantly influenced the particle size, % EE, 
and % cumulative drug release (CDR) that is 
very much evident from the results in table I. 
The in vitro drug release profiles of F1 to F8 are 
shown in figure 1. 
Based on the results obtained for particle 
size, % EE, the response polynomial 
coefficients were determined in order to 
evaluate each response. Each response 
coefficient was studied for its statistical 
significance. The non-significant response 
coefficients were deleted, and the following 
significant polynomial response equation(s) for 
particle size, % EE, were generated. 
Particle size  
Particle size (nm) = 546 + 0.215 Stearic 
acid (mg) - 0.136 Lecithin (mg) - 3.93 Stirring 
time (min) 
S = 10.8167   R-Sq = 99.0%   R-Sq(adj) = 
98.2% 
 
Entrapment efficiency (EE) 
EE (%) = 47.0 + 0.0444 Stearic acid 
(mg) - 0.000347 Lecithin (mg) + 0.0978 Stirring 
time (min)S = 0.836324   R-Sq = 99.6%   R-
Sq(adj) = 99.2%. 
These equations were utilized for 
validation of the experimental design. The 
response surface plots generated using 
polynomial equations represent simultaneous 
effect of any two variables on response 
parameter taking one variable at constant  level.  
 
 
Figure 1. In-vitro drug release of prepared SLN formulations 
 
 
Figure 2. Response surface plots showing particle size as dependent variables plotted against two 
independent parameters (stearic acid and homogenization time) taking one parameter (lecithin 
amount) as constant of the prepared SLN formulations. 
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On carefully observing these plots, the 
qualitative effect of each variable on each 
response parameter can be visualized. Figure 2 
shows response surface plots with particle size 
as dependent variables plotted against two 
independent parameters (stearic acid and 
homogenization time) taking one parameter 
(lecithin amount) as constant.  
Response graph shows the variation in 
independent variables strongly affect the 
dependent variable. The wavy surface show 
more variations in dependent variable on 
increasing or decreasing the value of 
independent variable and almost straight 
surface denote less variation in dependent 
variable for same condition. 
The release kinetics was evaluated by 
fitting the data into first order (r2 = 0.7421), 
zero order (r2 = 0.9428), Higuchi (r2 = 0.9747) 
and Peppas equations (r2 = 0.9330). Based on 
the results, the release of zolmitriptan from 
SLNs best-fitted Higuchi equation 
(r2 = 0.9747) and the possible mechanisms            
for the drug release from F8 might be         
diffusion of the drug from the matrix and 
matrix erosion resulting from degradation of              
lipids. A similar report has been made by             
other researchers as well (Souto, 2006 and        
Lai et al., 2009). Thus, the in-vitro release                    
data indicated that the optimized SLNs were 
capable of sustaining the release of 
zolmitriptan. 
 
 
 
Figure 3. Transmission electron microscopy (TEM), with magnification 
150 KX. 
 
 
 
Figure 4. Atomic force microscopy (AFM) images of SLNs on 1µm scale. 
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Selection of optimized formulation 
Optimized formulation (F8) was selected 
on the basis of small particle size, higher 
entrapmentefficiency,andhigher in-
vitro  cumulative drug release after 24 h. The 
optimized formulation was then subjected to 
Zeta potential, TEM and AFM. 
 
Zeta potential and Polydispersity Index 
(PDI) 
The zeta potential was determined to be 
-35.3 ± 0.02 mV (n=3). The polydispersity 
index of 0.131 ± 0.12 (n=3) indicated a 
polydisperse colloidal dispersion. 
 
Transmission Electron Microscopy (TEM) 
TEM showed that the particles had 
round and uniform shapes. The means 
diameters of SLNs were in the range of 
approximately 260-290nm (Figure 3). 
 
Atomic force microscopy 
The AFM tapping mode images of 
ZOL-SLNs were observed. Both the planner 
and three-dimensional images are presented. 
The imaging showed that ZOL-SLNs had a 
spherical shape. The obtained images showed a 
clear topography of particles (Figure 4). 
 
CONCLUSION 
The present investigation demonstrated 
that particle size of the nanoparticles can be 
controlled by varying process variables such as 
homogenization time, amount of stearic acid 
used and the amount of lecithin. Solid lipid 
nanoparticles of zolmitriptan were successfully 
developed to yield an optimized formulation 
with least nanometeric particle size and highest 
possible entrapment efficiency that could 
sustain the release of drug for over 24h. Use of 
23 full-factorial design enabled to develop an 
acceptable formulation using minimum raw 
materials and in minimum time. 
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